Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482–90.

Article  CAS  PubMed  Google Scholar 

Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robinson TM, Bowman RL, Persaud S, Liu Y, Neigenfind R, Gao Q, et al. Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia. Sci Adv. 2023;9:eadg0488.

Article  CAS  PubMed  Google Scholar 

Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, et al. Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party. Hemasphere. 2022;6:e676.

Article  CAS  PubMed  Google Scholar 

Canali A, Vergnolle I, Bertoli S, Largeaud L, Nicolau ML, Rieu JB, et al. Prognostic impact of unsupervised early assessment of bulk and leukemic stem cell measurable residual disease in acute myeloid leukemia. Clin Cancer Res. 2023;29:134–42.

Article  CAS  PubMed  Google Scholar 

Li SQ, Xu LP, Wang Y, Zhang XH, Chen H, Chen YH, et al. An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood. 2022;140:516–20.

Article  CAS  PubMed  Google Scholar 

Ngai LL, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MAMA, Fayed MMHE, et al. Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial. Blood. 2023;141:2657–61.

CAS  PubMed  Google Scholar 

Blachly JS, Walter RB, Hourigan CS. The present and future of measurable residual disease testing in acute myeloid leukemia. Haematologica. 2022;107:2810–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Othus M, Gale RP, Hourigan CS, Walter RB. Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transpl. 2020;55:843–50.

Article  Google Scholar 

Walter RB, Ofran Y, Wierzbowska A, Ravandi F, Hourigan CS, Ngai LL, et al. Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations. Leukemia. 2021;35:1529–38.

Article  PubMed  Google Scholar 

Short NJ, Zhou S, Fu C, Berry DA, Walter RB, Freeman SD, et al. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis. JAMA Oncol. 2020;6:1890–9.

Article  PubMed  PubMed Central  Google Scholar 

Short NJ, Fu C, Berry DA, Walter RB, Freeman SD, Hourigan CS, et al. Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis. Leukemia. 2022;36:2817–26.

Article  PubMed  Google Scholar 

Short NJ, Rafei H, Daver N, Hwang H, Ning J, Jorgensen JL, et al. Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML. Blood Adv. 2020;4:6117–26.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, et al. Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023;7:3284–96.

Article  PubMed  PubMed Central  Google Scholar 

Ravandi F, Cloos J, Buccisano F, Dillon R, Döhner K, Freeman SD, et al. Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: roadmap from an ELN-DAVID expert panel. Am J Hematol. 2023; In press.

Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY, et al. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol. 2012;30:3625–32.

Article  PubMed  PubMed Central  Google Scholar 

Paras G, Morsink LM, Othus M, Milano F, Sandmaier BM, Zarling LC, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022;139:1694–706.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, et al. Effect of measurable (‘minimal’) residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia. Leukemia. 2016;30:2080–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rodríguez-Arbolí E, Othus M, Orvain C, Zarling LC, Sandmaier BM, Milano F, et al. Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Haematologica. 2023;108:273–7.

Article  PubMed  Google Scholar 

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378:1189–99.

Article  CAS  PubMed  Google Scholar 

Dillon LW, Gui G, Page KM, Ravindra N, Wong ZC, Andrew G, et al. DNA sequencing to detect residual disease in adults with acute myeloid leukemia prior to hematopoietic cell transplant. JAMA. 2023;329:745–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dillon LW, Higgins J, Nasif H, Othus M, Beppu L, Smith TH, et al. Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia. Haematologica. 2023; in press.

Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, et al. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38:1273–83.

Article  CAS  PubMed  Google Scholar 

Craddock C, Jackson A, Loke J, Siddique S, Hodgkinson A, Mason J, et al. Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia. J Clin Oncol. 2021;39:768–78.

Article  CAS  PubMed  Google Scholar 

Levis M, Hamadani M, Logan B, Jones R, Singh AK, Litzow M. et al. BMT-CTN 1506 (MORPHO): a randomized trial of the FLT3 inhibitor gilteritinib as post-transplant maintenance for FLT3-ITD AML. In Proceedings of 28th Congress of the European Hematology Association Frankfurt, Germany; 2023.

Burchert A, Bug G, Fritz LV, Finke J, Stelljes M, Röllig C, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020;38:2993–3002.

Article  PubMed  Google Scholar 

Schlenk RF, Montesinos P, Romero-Aguilar A, Vrhovac R, Patkowska E, Kim HJ. et al. Impact of allogeneic hematopoietic cell transplantation (allo‐HCT) in first complete remission (CR1) in addition to FLT3 inhibition with quizartinib in acute myeloid leukemia (AML) with FLT3–internal tandem duplication (FLT3‐ITD): results from the QuANTUM‐First trial [abstract]. Clin Lymphoma Myeloma Leuk. 2023;23:S521–2.

Article  Google Scholar 

Othman J, Potter N, Mokretar K, Taussig D, Khan A, Krishnamurthy P, et al. FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML. Leukemia. 2023;37:2066–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sartor C, Brunetti L, Audisio E, Cignetti A, Zannoni L, Cristiano G, et al. A venetoclax and azacitidine bridge-to-transplant strategy for NPM1-mutated acute myeloid leukaemia in molecular failure. Br J Haematol. 2023;202:599–607.

Article  CAS  PubMed  Google Scholar 

U.S. Department of Health and Human Services. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment—guidance for industry. 2020. Accessed 20 Oct 2023. https://www.fda.gov/media/134605/download.

U.S. Department of Health and Human Services. Acute myeloid leukemia: developing drugs and biological products for treatment - guidance for industry. 2022. Accessed 20 Oct 2023. https://www.fda.gov/media/162362/download.

Kapp-Schwoerer S, Weber D, Corbacioglu A, Gaidzik VI, Paschka P, Krönke J, et al. Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood. 2020;136:3041–50.

Article  CAS  PubMed  Google Scholar 

Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, et al. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 2022;139:2145–55.

Article  CAS  PubMed  Google Scholar